Bernd Brust has resigned as president of molecular medicine at Life Technologies.
Brust will continue to serve as a consultant to the company for two months ending Dec. 31, according to documents filed with the US Securities and Exchange Commission. He will receive $5,000 per month, continued vesting of his outstanding equity awards, and health benefits during the consulting period, and nine months of outplacement assistance.
Previously, Brust served as president of commercial operations at Life Tech and senior vice president of global sales at Invitrogen. He has also held various roles at GE Medical Systems Information Technologies. He holds a degree in engineering from MTS in Amsterdam.
Pacific Biosciences has appointed Michael Hunkapiller as executive chairman of its board of directors, which the company announced during a conference call to discuss its third-quarter results (see story, this issue). Hugh Martin will continue to serve as president and CEO.
Hunkapiller has served on the board of directors since 2005. He is a general partner at Alloy Ventures and former president and general manager of Applied Biosystems, which he co-founded. He was also a founder of Celera Genomics and senior vice president of Applera.
He holds a BS in chemistry from Oklahoma Baptist University and a PhD in chemical biology from California Institute of Technology.
Illumina has named Daniel Grosu as vice president and chief medical officer, a newly created position. In this role, Grosu will help build Illumina's diagnostic capabilities through collaborations with regulatory agencies, internal product development teams, and the company's CLIA-certified clinical laboratory.
Previously, Grosu was group director of clinical science and clinical and medical affairs at Ortho-Clinical Diagnostics. He has also served as director and global clinical leader of global clinical development and diagnostic imaging at Bayer Healthcare. He holds a BS and an MS from Wheaton College, an MD from Saint Louis University, and an MBA from the University of Oxford.
Patrice Milos has left Helicos BioSciences, where she was vice president and chief scientific officer, to become Boston site head and precision medicine lead for Pfizer's Centers for Therapeutic Innovation. She remains a senior scientific advisor for Helicos.
Milos joined Helicos in 2007 from Pfizer Global Research and Development, where she was executive director. She holds PhD and MS degrees from Rensselaer Polytechnic Institute and a BA from the College of Saint Rose.